New hope for hard-to-treat bowel cancer: combo therapy enters phase 2 trial
Disease control
Recruiting now
This study tests a new drug called TL938 combined with trastuzumab in people with HER2-positive colorectal cancer that has spread or come back and cannot be removed by surgery. About 80 adults who have already tried standard treatments will receive the combination to find the bes…
Phase: PHASE2 • Sponsor: Suzhou Teligene Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC